Andrew Galler

Stock Analyst at Morgan Stanley

(0.57)
# 4,101
Out of 5,046 analysts
29
Total ratings
33.33%
Success rate
-15.38%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Andrew Galler

Immunocore Holdings
Mar 7, 2025
Assumes: Equal-Weight
Price Target: $35
Current: $32.92
Upside: +6.32%
Amicus Therapeutics
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $14$15
Current: $9.03
Upside: +66.11%
Silence Therapeutics
Dec 9, 2022
Initiates: Equal-Weight
Price Target: $18
Current: $7.06
Upside: +154.96%
Arrowhead Pharmaceuticals
Nov 29, 2022
Maintains: Equal-Weight
Price Target: $41$37
Current: $42.39
Upside: -12.72%
Ionis Pharmaceuticals
Nov 10, 2022
Maintains: Overweight
Price Target: $57$56
Current: $74.30
Upside: -24.63%
Vir Biotechnology
Nov 4, 2022
Maintains: Underweight
Price Target: $15$18
Current: $5.96
Upside: +202.01%
PTC Therapeutics
Sep 9, 2022
Initiates: Equal-Weight
Price Target: $54
Current: $68.31
Upside: -20.95%
Halozyme Therapeutics
Sep 9, 2022
Initiates: Overweight
Price Target: $50
Current: $65.17
Upside: -23.28%
ADC Therapeutics
Nov 9, 2021
Initiates: Outperform
Price Target: $44
Current: $4.46
Upside: +886.55%
Moderna
Nov 9, 2021
Initiates: Outperform
Price Target: $304
Current: $27.16
Upside: +1,019.29%